Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. OBJECTIVE: To assess the incidence and characteristics of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Endocrinol Metab
Egile Nagusiak: de Filette, Jeroen, Jansen, Yanina, Schreuer, Max, Everaert, Hendrik, Velkeniers, Brigitte, Neyns, Bart, Bravenboer, Bert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Endocrine Society 2016
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5095250/
https://ncbi.nlm.nih.gov/pubmed/27571185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2016-2300
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak